TCMCB07

DRUG2 trials

Sponsors

Endevica Bio

Conditions

CachexiaCancer Weight Loss

Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

CompletedNCT05529849

Endevica BioCachexia

Start: 2022-07-12End: 2023-02-20Updated: 2024-02-21

Phase 2

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

RecruitingNCT06937177

Endevica BioCancer Weight Loss

Start: 2025-04-28End: 2027-12-01Target: 120Updated: 2026-07-15

Related Papers

Design of an innovative clinical development program using randomized controlled phase 2 trial data and real-world evidence from an expanded access protocol to assess mifomelatide (TCMCB07) in GI cancer cachexia.

Journal of Clinical Oncology2026-05-28

Abstract CT219: A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial

Cancer Research2026-04-17

Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects.

Journal of Clinical Oncology2023-06-013 citations